ZVSA Zyversa Therapeutics, Inc.

Fundamentals / CIK 0001859007 / USD

Zyversa Therapeutics, Inc. reported $742K in total assets and a net loss of $24.49M through December 31, 2025 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open ZVSA in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

4 fiscal years (2022 to 2025), reported in USD.

$0$0$0-$91.91MFY 2022 Net Income: -$14.05M2022FY 2023 Net Income: -$98.30M2023FY 2024 Net Income: -$9.41M2024FY 2025 Net Income: -$24.95M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Dec 31 Dec 31 Dec 31 Dec 12
Research & Development $1.11M $1.78M $3.21M $5.41M
Total Operating Expenses $25.49M $9.14M $107.8M $13.01M
Operating Income -$25.49M -$9.14M -$107.8M -$13.01M
EBITDA -- -$9.13M -$107.7M -$13.00M
Income Before Tax -$25.80M -$9.41M -$107.8M -$14.05M
Income Tax Expense -$852K $6.7K -$9.46M --
Net Income -$24.95M -$9.41M -$98.30M -$14.05M
Basic EPS -$4.18 -$8.48 -$1,089.70 -$1,101,223.58
Diluted EPS -$4.18 -$8.48 -$1,089.70 -$1,101,223.58
Basic Shares Outstanding 6.0M 1.1M 97.5K 22
Diluted Shares Outstanding 6.0M 1.1M 97.5K 22

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Research & Development $58K $79K $365K $410K $259K $121K $436K $709K
Total Operating Expenses $1.30M $552K $20.75M $2.04M $2.14M $1.29M $2.27M $2.75M
Operating Income -$1.30M -$552K -$20.75M -$2.04M -$2.14M -$1.29M -$2.27M -$2.75M
EBITDA -- -- -- -- -- -$1.29M -$2.27M -$2.75M
Income Before Tax -- -- -$20.66M -$2.21M -- -$1.42M -$2.40M -$2.75M
Income Tax Expense -- -- -$852K -- -- -- -- $9.7K
Net Income -$1.79M -$679K -$19.81M -$2.21M -$2.26M -$1.42M -$2.40M -$2.76M
Basic EPS -$0.22 -- -$2.56 -$0.46 -$0.73 -- -$2.43 -$3.31
Diluted EPS -$0.22 -- -$2.56 -$0.46 -$0.73 -- -$2.43 -$3.31
Basic Shares Outstanding 8.1M -- 7.7M 4.8M 3.1M -- 988.4K 834.9K
Diluted Shares Outstanding 8.1M -- 7.7M 4.8M 3.1M -- 988.4K 834.9K

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Dec 31 Dec 31 Dec 31 Dec 31 Dec 31
Cash & Cash Equivalents $102K $1.53M $3.14M $5.90M $928K
Cash & Short-Term Investments $102K $1.53M $3.14M $5.90M $928K
Total Current Assets $463K $1.72M $3.35M $6.36M $1.18M
Property, Plant & Equipment, Net -- -- $6.9K $17K --
Goodwill -- -- -- $11.90M --
Intangible Assets -- -- -- $100.1M --
Other Non-Current Assets -- $18.65M $18.65M $100.1M --
Total Non-Current Assets $0 $18.88M $18.76M $112.1M $75.96M
Total Assets $463K $20.60M $22.11M $118.5M $77.14M
Accounts Payable $10.12M $9.34M $8.43M $6.03M --
Total Current Liabilities $12.85M $11.23M $10.19M $8.19M $277K
Total Non-Current Liabilities $0 $852K $845K $10.32M $3.38M
Total Liabilities $12.85M $12.08M $11.04M $18.51M $3.65M
Total Debt (incl. Leases) -- -- $8.7K $109K --
Common Stock $809 $251 $40 $26 $32
Retained Earnings -$137.6M -$112.6M -$103.2M -$4.92M -$2.26M
Total Stockholders' Equity -$12.39M $8.52M $11.07M $99.66M -$2.26M
Total Equity -$12.39M $8.52M $11.07M $99.66M -$2.26M

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Cash & Cash Equivalents $303K $102K $528K $72K $1.61M $1.53M $123K $119K
Cash & Short-Term Investments $303K $102K $528K $72K $1.61M $1.53M $123K $119K
Total Current Assets $742K $463K $996K $549K $2.11M $1.72M $390K $641K
Property, Plant & Equipment, Net -- -- -- -- -- -- -- $1.7K
Other Non-Current Assets -- -- -- -- $18.65M $18.65M $18.65M $18.65M
Total Non-Current Assets $0 $0 $45K $19.09M $18.88M $18.88M $19.03M $18.83M
Total Assets $742K $463K $1.04M $19.64M $20.99M $20.60M $19.42M $19.47M
Accounts Payable $10.24M $10.12M $9.81M $9.77M $9.60M $9.34M $9.28M $8.32M
Total Current Liabilities $14.87M $12.85M $12.77M $12.69M $12.00M $11.23M $11.54M $9.99M
Total Non-Current Liabilities $0 $0 $0 $852K $852K $852K $855K $855K
Total Liabilities $14.87M $12.85M $12.77M $13.54M $12.86M $12.08M $12.40M $10.85M
Common Stock $809 $809 $809 $487 $257 $251 $107 $83
Retained Earnings -$139.4M -$137.6M -$136.9M -$117.1M -$114.9M -$112.6M -$111.2M -$108.8M
Total Stockholders' Equity -$14.12M -$12.39M -$11.73M $6.10M $8.13M $8.52M $7.03M $8.62M
Total Equity -$14.12M -$12.39M -$11.73M $6.10M $8.13M $8.52M $7.03M $8.62M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Dec 31 Dec 31 Dec 31 Dec 12
Net Income -$24.95M -$9.41M -$98.30M -$14.05M
Depreciation & Amortization -- $6.9K $10K $9.9K
Stock-Based Compensation $223K $706K $1.19M $3.52M
Change in Payables $689K $889K $2.41M $6.62M
Operating Cash Flow -$5.11M -$7.52M -$8.72M -$1.49M
Common Stock Issued -- $1.35M -- --
Financing Cash Flow $3.69M $5.91M $5.96M $1.87M
Net Change in Cash -$1.43M -$1.61M -$2.76M $371K

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Net Income -$1.79M -$679K -$19.81M -$2.21M -$2.26M -$1.42M -$2.40M -$2.76M
Depreciation & Amortization -- -- -- -- -- $0 $1.7K $2.6K
Stock-Based Compensation $56K $17K $74K -$22K $154K $161K $161K $161K
Change in Payables $112K $318K $315K -$135K $191K $212K $791K $189K
Operating Cash Flow -$799K -$414K -$1.41M -$1.52M -$1.77M -$1.21M -$614K -$1.91M
Financing Cash Flow $1.00M -$13K $1.86M -$18K $1.85M $2.62M $618K $0
Net Change in Cash $201K -$426K $456K -$1.54M $81K $1.41M $3.4K -$1.91M

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Dec 31 Dec 31 Dec 31 Dec 12
Return on Equity (ROE) -- -110.5% -887.6% -14.1%
Return on Assets (ROA) -5384.0% -45.7% -444.5% -11.9%
Current Ratio 0.04x 0.15x 0.33x 0.78x
Quick Ratio 0.01x 0.14x 0.31x 0.72x
Debt to Equity -- -- 0.00x 0.00x

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Return on Equity (ROE) -- -- -- -135.9% -108.8% -110.5% -303.5% -253.3%
Return on Assets (ROA) -3299.4% -5384.0% -2470.1% -42.2% -42.1% -45.7% -109.8% -112.1%
Current Ratio 0.05x 0.04x 0.08x 0.04x 0.18x 0.15x 0.03x 0.06x
Quick Ratio 0.02x 0.01x 0.04x 0.01x 0.13x 0.14x 0.01x 0.01x
Source: SEC EDGAR CompanyFacts (CIK 0001859007) · from June 30, 2021 Data through March 31, 2026 · synced Nov 21, 2026, 05:16 UTC · Open in terminal